DKSH has entered into a strategic partnership with SciGen for the supply of zometa, a lifesaving oncology medicine, to Việt Nam. — Photo courtesy of DKSH

DKSH, a leading market expansion services provider, has signed a strategic partnership with SciGen for the supply of zometa, a lifesaving cancer medicine, to the Vietnamese market.

The imported products will be distributed by local distributors engaged by DKSH.

SciGen is a biopharmaceutical company that sells innovative and affordable healthcare products globally.

It leverages commercialisation and networking capabilities to in-licenses and distribute branded pharmaceutical products and medical devices to treat endocrinological and oncological diseases.

The partnership with DKSH plays a key role in SciGen’s plans to expand to this promising market with zometa, a bone-targeted agent for skeletal complications in advanced cancers and multiple myeloma. It is made at its facilities in Europe.

Dr Shazli Ahmed Khan, SciGen’s region commercial head for Asia growth markets, said: "Việt Nam is a key market in SciGen’s Asian footprint, and the organisation is committed to partnering with local healthcare organisations to achieve this objective for the benefit of Vietnamese patients.

Phillip Wray, general director, DKSH Pharma Vietnam, said: "We are delighted to be a trusted partner to SciGen in expanding its business in Việt Nam. By utilising our global experience and local understanding, as well as collaboration with local distributors, we will share the same vision to improve accessibility of the high-quality oncology drug zometa, across Việt Nam." — VNS